Sort   by:  
 Page size 
UnknownQuality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls.
Not available
S-EPMC3595422 | biostudies-literature
UnknownLong-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Not available
S-EPMC4500829 | biostudies-literature
UnknownUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Not available
S-EPMC5846188 | biostudies-literature
UnknownNeuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Not available
S-EPMC3732004 | biostudies-literature
UnknownRisk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Not available
S-EPMC4302215 | biostudies-literature
UnknownPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Not available
S-EPMC4162494 | biostudies-literature
UnknownOptimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Not available
S-EPMC5455310 | biostudies-literature
UnknownTranslational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Not available
S-EPMC5070554 | biostudies-literature
UnknownPhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Not available
S-EPMC4534525 | biostudies-literature
UnknownRandomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Not available
S-EPMC3532391 | biostudies-literature
Sort   by:  
 Page size